Key Highlights
- 41 public‑health technologies were handed over to commercial partners for scale‑up and distribution.
- First ever transfer of inactivated Kyasanur Forest Disease and Chandipura virus biomaterials to industry.
- More than 100 cutting‑edge diagnostics, therapeutics, devices and startup solutions were exhibited.
- Two flagship reports – a biomedical‑patent landscape analysis and a technology compendium – were released.
Detailed Insights
The Indian Council of Medical Research (ICMR) hosted the Medical Innovations Patent Mitra: Innovators‑to‑Industry (I2I) Connect at Delhi’s Manekshaw Centre, establishing one of the nation’s inaugural structured ecosystems devoted exclusively to biomedical innovation and technology transfer. The platform, an outgrowth of ICMR’s Patent Mitra programme, seeks to eliminate the longstanding bottleneck that leaves promising laboratory discoveries stranded due to insufficient commercialization pathways.
By linking researchers, startups, manufacturers and investors in a single venue, the event facilitated the migration of 41 technologies – spanning advanced diagnostics, vaccines, medical devices and public‑health solutions – toward large‑scale production and market entry. Notably, ICMR transferred well‑characterised inactivated biomaterials for Kyasanur Forest Disease (KFD) and Chandipura virus, marking a historic first for India and bolstering domestic vaccine‑development capacity.
Beyond the transfers, over a hundred innovations were showcased, drawing direct dialogue among innovators and industry stakeholders. The initiative also introduced two seminal documents: the Indian Biomedical Patent Landscape Report, which charts the country's patent ecosystem, and a Technology Compendium detailing all transfer‑ready health technologies.
Key Concepts
- Technology Transfer: The systematic process of moving scientific discoveries from research institutions to commercial entities for development, manufacture and distribution.
- Patent Mitra Programme: ICMR’s framework that safeguards biomedical IP, supports licensing, and connects inventors with industry partners.
- Biomaterials (KFD & Chandipura): Inactivated viral components used as reference standards and research tools for vaccine development and epidemiological preparedness.